Related Experiment Videos
Positron emission tomography in urological oncology
C K Hoh1, M A Seltzer, J Franklin
1Department of Urology, UCLA School of Medicine, Los Angeles, California, USA.
The Journal of Urology
|July 2, 1998
Summary
Positron emission tomography (PET) offers valuable insights into urological diseases. While not always definitive for prostate cancer, PET shows promise in staging testicular cancer and monitoring renal cell carcinoma treatment.
Area of Science:
- Nuclear Medicine
- Urology
- Oncology
Background:
- Positron emission tomography (PET) is an advanced imaging technique.
- Its application in urological research and clinical practice is expanding.
- Understanding PET principles is crucial for interpreting urological studies.
Purpose of the Study:
- To introduce the fundamental principles and methodologies of PET.
- To review current and emerging research and clinical uses of PET in urology.
- To enable objective review of PET-based urological literature.
Main Methods:
- A comprehensive literature search was conducted.
- Recent applications of PET in urology were identified and reviewed.
Main Results:
- Prostate Cancer: 18-fluoro-2-deoxyglucose (FDG) PET showed limitations in differentiating benign from malignant prostate tissue and detecting bone metastases but may aid in identifying lymph node metastases in recurrent cases.
- Renal Cell Carcinoma: FDG PET demonstrated efficacy in detecting primary and metastatic lesions and monitoring therapeutic response.
- Testicular Cancer: FDG PET assisted in distinguishing viable cancer from benign changes in teratomas and fibrotic/necrotic areas.
Conclusions:
- Advancements in PET technology enhance tumor staging accuracy before surgery.
- PET is emerging as a valuable tool for monitoring treatment efficacy in urological malignancies.
- PET holds significant potential for both research and clinical management of urological diseases.